Trials / Recruiting
RecruitingNCT05965024
Exploration on the Value of MRD Based on ctDNA Detection in Predicting Recurrence of Resected Non-small Cell Lung Cancer
Exploration on the Value of Molecular Residual Disease Based on Circulating Tumor DNA Detection in Predicting Recurrence of Resected Non-small Cell Lung Cancer
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 377 (estimated)
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
Based on the unique patented MONOD and Methyl Titan methylation sequencing technology on lung cancer tissue and blood samples, a lung cancer MRD monitoring panel is designed. The panel is used to detect molecular residual disease of stage IB-IIIB non-small cell lung cancer patients underwent radical surgery, explore personalized analysis models, and conduct research on recurrence monitoring for non-small cell lung cancer patients.
Conditions
Timeline
- Start date
- 2023-10-25
- Primary completion
- 2026-08-01
- Completion
- 2028-08-01
- First posted
- 2023-07-28
- Last updated
- 2024-02-21
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05965024. Inclusion in this directory is not an endorsement.